Form 4: Xtant Medical Holdings Director Jonn R. Beeson Reports Stock Award and Holdings

Director Jonn R. Beeson reports acquisition of deferred stock units and adjustments to his holdings in Xtant Medical Holdings, Inc.

Summary

• On August 15, 2024, Jonn R. Beeson, a director of Xtant Medical Holdings, Inc., reported transactions involving the company's common stock.
• Beeson acquired 162,162 shares through a deferred stock unit award, which vests on August 15, 2025, contingent on his continued service as a director.
• The acquisition price for these shares was $0.
• Following the reported transaction, Beeson directly owns 359,391 shares of common stock, which includes 307,342 shares issuable upon settlement of deferred stock units.
• Beeson also indirectly owns 1,015,272 shares through The Platinum Legacy Trust, dated February 24, 2017, where he serves as trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports transactions. The acquisition of stock units could be seen as a positive sign of confidence, but it's a standard practice for director compensation.

Positives

• The acquisition of deferred stock units aligns the director's interests with the long-term performance of the company.
• Continued service as a director is required for the vesting of the stock units, incentivizing commitment to the company.

Risks

• The vesting of the deferred stock units is contingent upon Beeson remaining a director, creating a potential risk if he were to leave the company before August 15, 2025.

Future Outlook

The director's future stock ownership is tied to continued service with the company, suggesting a commitment to Xtant Medical Holdings.

Industry Context

This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and activities of company directors.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding director stock ownership.
• The vesting conditions may incentivize the director to act in the best interests of the company and its shareholders.

Key Dates